Fluvoxamine is a well-tolerated, widely available, inexpensive selective serotonin reuptake inhibitor that has been shown in a small, double-blind, placebo-controlled, randomized study to prevent clinical deterioration of patients with mild coronavirus disease 2019 (COVID-19). Fluvoxamine is also an agonist for the sigma-1 receptor, through which it controls inflammation. We review here a body of literature that shows important mechanisms of action of fluvoxamine and other SSRIs that could play a role in COVID-19 treatment. These effects include: reduction in platelet aggregation, decreased mast cell degranulation, interference with endolysosomal viral trafficking, regulation of inositol-requiring enzyme 1α-driven inflammation and increased melatonin levels, which collectively have a direct antiviral effect, regulate coagulopathy or mitigate cytokine storm, which are known hallmarks of severe COVID-19.
【저자키워드】 SARS-CoV-2, Inflammation, Cytokine storm, Interleukins, acute respiratory distress syndrome, 【초록키워드】 COVID-19, Treatment, coronavirus disease, melatonin, severe COVID-19, Antiviral effect, Coagulopathy, Patient, fluvoxamine, Control, Platelet, Mild, receptor, inhibitor, placebo-controlled, mechanism, regulate, Clinical deterioration, double-blind, Serotonin, Regulation, enzyme, randomized study, aggregation, hallmark, selective, degranulation, Effect, mitigate, Prevent, Cell, shown, reduction in, endolysosomal, 【제목키워드】 COVID-19, review, role, Action,